Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy

By: Cosylab via Business Wire

June 08, 2026 at 02:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared.

"PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it."

Physics-accurate, radiobiologically informed planning

PlanOne™ is built on a GPU-accelerated Monte Carlo dose engine for particle therapy, which serves as the physical foundation for accurate LET calculation and variable RBE modelling*. Clinical teams can plan with confidence and can review plans within a single planning workflow.

Full control over plan robustness

PlanOne™ provides comprehensive user-defined robust optimization, analysis and evaluation. Beyond the worst-case scenario approach, PlanOne™ supports an all-scenario scheme across the full set of user-defined scenarios simultaneously, resulting in treatment plans that reflect physical reality without compromising the plan’s robustness.

One environment. The OIS you already have.

Contouring, planning, and review take place within a single environment, and purpose-built tools support the demands of proton and heavy-ion treatment planning. PlanOne™ integrates with existing oncology information systems, helping preserve established workflows while reducing the need for data migration.

About Cosylab

Cosylab is a software and control systems company headquartered in Ljubljana, Slovenia. With over 20 years of experience and more than 1,000 projects across particle accelerators, radiation therapy devices, and oncology information systems, Cosylab develops complex software for the world's most technically demanding environments. PlanOne™ V1.0 is Cosylab's FDA 510(k) cleared treatment planning system for particle therapy.

PlanOne™ V1.0 is FDA 510(k) cleared. Items marked with * are in preparation for regulatory submission or under development; not yet available for sale and/or clinical use in any market. Market availability is subject to regulatory approval. PlanOne is a trademark of Cosylab d.d., registered in the United States and the European Union.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260607163098/en/

Contacts

For more information, contact:

Media contact: Petra Balažic, petra.balazic@cosylab.com

Product info: cosylab.com/planone, planone@cosylab.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	244.16	+1.49 (0.61%)
AAPL	312.66	+4.03 (1.31%)
AMD	552.05	+34.23 (6.61%)
BAC	59.90	+1.17 (1.99%)
GOOG	364.90	+8.72 (2.45%)
META	600.29	+17.39 (2.98%)
MSFT	386.74	-3.75 (-0.96%)
NVDA	195.55	+0.72 (0.37%)
ORCL	143.76	+3.49 (2.49%)
TSLA	419.77	+26.32 (6.69%)